Header

UZH-Logo

Maintenance Infos

Alicaforsen in the treatment of pouchitis


Greuter, Thomas; Rogler, Gerhard (2017). Alicaforsen in the treatment of pouchitis. Immunotherapy, 9(14):1143-1152.

Abstract

Alicaforsen is a 20-base antisense oligonucleotide inhibiting ICAM-1 production, which is an important adhesion molecule involved in leukocyte migration and trafficking to the site of inflammation. Hitherto, alicaforsen has been granted orphan drug designation and is prescribed as an unlicensed medicine in accordance with international regulation for the treatment of pouchitis and left-sided ulcerative colitis. Given the positive results evolving from one open-label trial and one case series in patients with chronic refractory pouchitis, US FDA has agreed to a rolling submission for a license application for the treatment of pouchitis, which has been recently initiated. Whether alicaforsen leads to higher endoscopic and clinical remission rates as placebo and whether the response can be maintained in the long-term in larger studies is yet unknown. An ongoing multicenter international Phase III trial will definitely address these unanswered questions.

Abstract

Alicaforsen is a 20-base antisense oligonucleotide inhibiting ICAM-1 production, which is an important adhesion molecule involved in leukocyte migration and trafficking to the site of inflammation. Hitherto, alicaforsen has been granted orphan drug designation and is prescribed as an unlicensed medicine in accordance with international regulation for the treatment of pouchitis and left-sided ulcerative colitis. Given the positive results evolving from one open-label trial and one case series in patients with chronic refractory pouchitis, US FDA has agreed to a rolling submission for a license application for the treatment of pouchitis, which has been recently initiated. Whether alicaforsen leads to higher endoscopic and clinical remission rates as placebo and whether the response can be maintained in the long-term in larger studies is yet unknown. An ongoing multicenter international Phase III trial will definitely address these unanswered questions.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

113 downloads since deposited on 19 Jan 2018
72 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gastroenterology and Hepatology
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Immunology and Allergy
Life Sciences > Immunology
Health Sciences > Oncology
Language:English
Date:November 2017
Deposited On:19 Jan 2018 13:27
Last Modified:08 Apr 2020 22:35
Publisher:Future Medicine
ISSN:1750-743X
OA Status:Green
Publisher DOI:https://doi.org/10.2217/imt-2017-0085
PubMed ID:29067882

Download

Green Open Access

Download PDF  'Alicaforsen in the treatment of pouchitis'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 340kB
View at publisher